The old way of producing recombinant proteins comes with an enormous environmental price tag. With a looming climate crisis and rising demand for growth factors and proteins, the world desperately needs a new paradigm in recombinant protein production.
Future Fields, a company based in the province of Alberta, Canada, is the first to harness the sustainability, scalability, and scientific elegance of fruit flies to manufacture cost-effective proteins. Their EntoEngine™ platform produces serum-free, bioactive growth factors and other recombinant proteins more sustainably than traditional expression systems, taking a big bite out of energy use, waste, and CO2 emissions.
The EntoEngine™ platform optimises the production of critical products across a broad range of industries and applications including cellular agriculture, research, therapeutics, vaccines, growth factors, and enzymes – all within a circular economy framework.
Future Fields Recombinant Bovine FGF2
Future Fields Recombinant Bovine FGF2 (> 95% purity) produced with the EntoEngine™ expression platform fulfils the needs of FGF2 requirements in cell culture across a variety of land-dwelling and aquatic species.
Their purified bovine FGF2 is a high-performing drop-in replacement for commercially available recombinant FGF2 in driving the proliferation of cells that express FGF receptors. Purified Bovine FGF2 produced in the EntoEngine™ has been confirmed to activate the FGF receptors via the activation of ERK1/2 pathways. Future Fields uses proprietary extraction and purification technologies to produce functional high-quality FGF2 that is ready for cell cultures.
Their purified FGF2 comes as a lyophilized powder, which when reconstituted is ready to be supplemented into cell culture media.
Future Fields Recombinant Human FGF2
Future Fields Recombinant Human FGF2 (> 95 % purity) produced with the EntoEngine™ expression platform fulfils the needs of FGF2 requirements in cell culture across a variety of cell lines, including but not limited to pluripotent and multipotent cells of various origins.
Their purified Recombinant Human FGF2 is a high-performing, bioactive, drop-in replacement for commercially available recombinant FGF2 in driving proliferation of cells that express FGF-receptors. It has been confirmed to activate the FGF receptors via Surface Plasmon Resonance (SPR) and cell proliferation and activation studies on NIH 3T3 lines.
Their purified Recombinant Human FGF2 comes as lyophilized powder, which when reconstituted is ready to be supplemented into cell culture media.
Future Fields, as a pioneering biotechnology company that has built the world's first synthetic biology system to use fruit flies, has achieved the esteemed ACT Environmental Impact Factor Label from My Green Lab, a nonprofit organisation with the mission to build a global culture of sustainability in science.